Major Depressive DisorderPsyMot-DepNCT06234176
Impact of Psychomotor Therapy on the Quality of Life in Depression
A study testing Personalised psychomotor therapy and Usual treatment in people with Major Depressive Disorder, run by Centre Hospitalier Esquirol at 1 site in France.
Trial summary
The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear. The investigators will assess how the participants' quality of life and psychomotor profile change over time. Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Major Depressive Disorder
- What is being tested?
- Personalised psychomotor therapy and Usual treatment
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 128 participants
- Where
- 1 siteFrance
- Study dates
- 1 Apr 2024to Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Diagnosis of depressive episode according to DSM-5 criteria.
- HDRS > 16
- Hospitalized or followed-up in one of the participating centers.
- Affiliated or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).
Who cannot join
- Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders)
- Sensory impairment or proven neurological pathology
- History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes)
- Limited functional ability (difficulty in moving about, performing manual tasks or moving about)
- Inability to understand questionnaires and study information
- Inability to travel to the inclusion center (personal vehicle, public transport)
- Pregnant or breast-feeding women, on declaration
- Forced hospitalization, subjects under guardianship or trusteeship, lack of social protection
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CH Esquirol
Limoges, 87000
Aude PAQUET, +33555431127, aude.paquet@ch-esquirol-limoges.fr
About this study
Official title: Influence of Psychomotor Therapy on Quality of Life in Patients With a Major Depressive Disorder: a Randomized Controlled Trial
The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear.
The investigators will assess how the participants' quality of life and psychomotor profile change over time.
Read more
The study aims to compare the quality of life at 3 months between patients who received 3 months of personalised psychomotor therapy in addition to standard treatment and those who received standard treatment alone.
The study lasted for 6 months, and the investigators expects a total of 128 people to participate in this research across several hospital establishments. This study evaluates the effectiveness of two types of treatment, divided into two randomly selected groups.
To participate, individuals must have a medical diagnosis of major depressive disorder (MDD) and be between the ages of 20 and 60.
They must have depressive symptoms with an HDRS score greater than 16 and provide informed consent. They must be treated or hospitalised at the Centre Hospitalier Esquirol or the Centre Hospitalier Henri Laborit (France).
After providing consent, they will undergo an initial clinical interview that evaluates anxiety, self-esteem, pleasure, and quality of life. The therapist assessed the participant's muscle tone, gross motor skills, praxis, manual dexterity, rhythm, processing of sensory information, and body image.
Following the assessment, the participant was randomly assigned to either the experimental or control group.
The experimental group received the usual treatment for depression and underwent psychomotor therapy once a week for 12 weeks.
The control group received the standard treatment for depression and underwent weekly telephone interviews.
An assessment is scheduled at 1 month to evaluate the participant's health status, including any changes to treatment and assessment of anxiety and depressive symptoms.
Another interim check-up is scheduled at 3 months to assess the patient's health status. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.
A final visit will be scheduled at 6 months for an assessment of the participant's health. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.
Read the detailed description
Hypothesis is that personalised weekly psychomotor therapy for 3 months (period of remission of depression) has a positive influence on the quality of life over time of people with MDD by improving their clinical (anxiety/anhedonia/psychomotor impairment) and psychomotor symptoms.
In this study, the investigators propose to compare the quality of life of two groups of participants: a group receiving one psychomotor therapy session per week in addition to the usual treatments for depression, and a group receiving the usual treatments for depression. The investigators will evaluate changes in quality of life and psychomotor profile over time (at 3 and 6 months).
Based on the results of our pilot study, the psychomotor examination will include an assessment of muscle tone, gross motor skills, praxis, manual dexterity, rhythm using the NP-MOT battery, sensory processing and body image.
Main objective To compare the quality of life at 3 months (M3) between MDD patients receiving 3 months of personalised psychomotor therapy in addition to standard treatment (GP) and those receiving standard treatment alone (GC).
Secondary objectives
- To compare changes in quality of life over time between D0/M3, D0/M6 and M3/M6 in patients in the GP and GC groups; a difference between the groups will be sought.
- Identify the psychomotor assessment items (tone, general motor skills, praxis, rhythm, body image, sensory profile) that differ at inclusion (D0) and 3 months (M3) between the GP and GC groups.
- To identify clinical factors of depression (intensity of depression, anxiety, psychomotor slowing, anhedonia) associated with a difference in psychomotor profile at M3 between the GP and GC groups.
- Identify items predictive of clinical improvement in depression based on psychomotor assessment items (tone, general motor skills, praxis, rhythm, body image, sensory profile) at 6 months (M6) in patients in the GP and GC groups.
- Evaluate at M3, in the GP group, the number of sessions completed and the therapeutic alliance using a scale.
Primary outcome measure Difference at M3 between the GP and GC groups in the quality of life score assessed using the SF-36 (Short-Form 36 Health Survey) scale.
Secondary outcome measures
- Difference between D0 and M3, D0 and M6, M3 and M6 in quality of life scores based on the SF-36. Change in Duke Health Profile scores over the 12 weeks of follow-up (S1 to S12).
- Number and nature of assessment items that differ at inclusion and 3 months between GP and GC using the Neuropsychomotor Function Assessment Battery (NP-MOT), Body Image Questionnaire (BIQ), Multidimensional Assessment of Interoceptive Awareness Version 2 (MAIAI-2), Adolescent/Adult Sensory Profile (AASP) tools
- Depression intensity score on the Hamilton Depression Rating Scale (HDRS), anxiety intensity score on the Hamilton Anxiety Rating Scale (HARS), psychomotor slowing down score on the CORE scale, anhedonia score on the SHAPS scale, and body image score on the QIC and MAIA-2 scales, sensory profile scores on the AASP scale, frequency of tonic-emotional manifestations, sub-scores of the NP-MOT battery, at M3.
- Clinical improvement score: 50% reduction in HDRS score, scores AASP, score QIC, score MAIA-2 and items sub-scores NP-MOT
- Total number of sessions and score on the French version of the Therapeutic Alliance Session Rating Scale at M3
The inclusion criteria for participants in this study are as follows: being between the ages of 20 and 60, having a diagnosis of major depressive disorder according to DSM-5 criteria, having a HDRS score greater than 16 indicating major symptoms, and being hospitalized or receiving care at one of the participating centres.
Additionally, participants must be affiliated with or benefiting from a social security scheme.
The participant and investigator must sign a written consent form that is both free and informed. This must be completed no later than the day of inclusion and before any required research examinations.
Non-inclusion criteria for this study are: psychiatric co-morbidity (excluding tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders), sensory disability or known neurological pathology, history of neurological damage to the brain (especially strokes, tumours, trauma resulting in loss of consciousness lasting more than 10 minutes), and limited functional ability (difficulty moving about, performing manual tasks or moving about).
Participants may be excluded from the study if they are unable to understand the questionnaires or related information, unable to travel to the inclusion centre via personal vehicle or public transport, pregnant or breastfeeding (as declared), subject to compulsory hospitalisation or under guardianship or trusteeship, or lack social protection.
The research is conducted as follows:
- Pre-selection by the coordinating investigator or co-investigator, validation of participation criteria by the referring doctor and information of participants by the referring doctor or coordinating investigator or staff associated with the research.
- Reflection period: between 24 and 72 hours.
- V0: Inclusion Collect of written consent, Socio-demographic data (age, sex, family situation, profession, place of residence, environment), psychiatric history, treatments received (medicinal and non-medicinal), etc.
Quality of life scale (SF36) Clinical assessments: Hamilton Depression Rating Scale (HDRS); Hamilton Anxiety Rating Scale (HARS); psychomotor slowing down scale (CORE), Rosenberg Self-Esteem Scale (EES-10), Anhedonia Scale (SHAPS) Psychomotor assessment: sensory profile (AASP), body image (QIC, MAIA-2), tone (NP-MOT); general motor skills (NP-MOT), rhythm (NP-MOT); praxis (NP-MOT); manual dexterity (PPT) Randomisation: allocation of patients by drawing lots to the GP (personalised psychomotor therapy in addition to standard treatment) or GC (standard treatment) groups.
GP: Personalised psychomotor therapy: 1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale.
The sessions will be based on static and dynamic body exercises involving muscle relaxation, breathing, sensations and moving the body. For each session the Session Rating Scale will be use.
GC: Usual care for 3 months with a weekly telephone interview + Duke's Health Scale.
- V1: visit at 1 month ± 4 days for an interim assessment Treatments received and/or modified in the last 4 weeks Clinical assessments: HDRS; HARS; CORE, EES-10, SHAPS
- V2: visit at 3 months ± 7 days Treatments received and/or modified in the last 3 months Clinical assessments: HDRS; HARS; CORE, EES-10, SHAPS Number of psychomotricity sessions performed Quality of life scale (SF36) Blind psychomotor assessment: AASP, QIC, MAIA-2, NP-MOT
- V3: visit at 6 months ± 7 days Treatments received and/or modified in the last 3 months Clinical assessments: HDRS; HARS; CORE, EES-10, SHAPS Quality of life scale (SF36) Blind psychomotor assessment: AASP, QIC, MAIA-2, NP-MOT Participants in the GC group were offered 12 sessions of psychomotor therapy.
At V2, the psychomotor assessment will be carried out by a psychomotor therapist who has not provided psychomotor therapy to the participant.
- Conditions
- Major Depressive Disorder
- Being tested
- Personalised psychomotor therapy, Usual treatment
- Keywords
- psychomotor therapy, quality of life, major depressive disorder, psychomotor profile, sensory processing
- Medical subject headings
- Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Personalised psychomotor therapyBehavioural
Also called GP
The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment.
The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation.
Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions.
The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted.
During each session, the participant will be required to complete the Duke health profile.
Usual treatmentOther
Also called GC
Participants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability.
| Study group | Role | What they receive |
|---|---|---|
| Personalised psychomotor therapy group | Experimental | 1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale. Receives: Behavioral: Personalised psychomotor therapy |
| Usual treatment group | Active comparator | Standard treatment for depression administered by a doctor + a weekly telephone interview for 12 weeks to administer the Duke Health Scale. Receives: Other: Usual treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in quality of life assessed using the Short-Form 36 Health Survey
Difference between GP and GC groups in quality of life score
Measured: at 3 month
Secondary outcomes (12)
Difference in time of quality of life using the Short-Form 36 Health Survey
Difference between D0 and M3, D0 and M6, M3 and M6 in quality of life scores
Measured: first day to 6th month
Evolution of quality of life using the Duke health profile
Evolution of Duke health profile scores from week 1 to week 12 in both GP and GC groups
Measured: first day to 6th month
Difference in psychomotor profile
Number and nature of assessment items that differ at 1 and 3 months between GP and GC using NP-MOT, QIC, MAIA-2, AASP tools
Measured: 3th and 6 th month
Description of depression intensity using the Hamilton Depression Rating Scale
clinical improvement concerning depression low score to Hamilton Depression Rating Scale indicate a low depressive intensity
Measured: at 3 month
Description of anxiety intensity using the Hamilton Anxiety Rating Scale
clinical improvement concerning anxiety low score to Hamilton Anxiety Rating Scale indicate a low anxiety intensity
Measured: at 3 month
Description of psychomotor slowing using the CORE scale
clinical improvement concerning psychomotor slowing low score to CORE Scale indicate a low psychomotor slowing
Measured: at 3 month
Description of anhedonia using the Snaith-Hamilton Pleasure Scale
clinical improvement concerning anhedonia low score to Snaith-Hamilton Pleasure Scale indicate a low anhedonia intensity
Measured: at 3 month
Description of body image using the Multidimensional Assessment of Interoceptive Awareness
clinical improvement concerning body image low score to Multidimensional Assessment of Interoceptive Awareness indicate a low interoceptive awarness
Measured: at 3 month
Description of sensory profile using the Adolescent Adult Sensory Profile
clinical improvement concerning sensory profile The AASP is composed by four subscores
- norm for low registration subcore is between 24-35
- norm for sensation seeking subcore is between 43-56
- norm for lsensory sensitivity subcore is between 26-41
- norm for sensation avoiding subcore is between 27-41
Measured: at 3 month
Frequency of tonic-emotional manifestations
observed reactions: awkward gestures, reassurance gestures, fixed smile, facial rictus, rigid body posture, contorting, stiffening, slightly theatrical posture, emotional uncontrol, neurovegetative manifestations: presence or absence
Measured: at 3 month
Frequency of psychomotor impairment using the NP-MOT battery
Measured: at 3 month
Frequency of sessions
Therapeutic alliance is mesured by number of sessions completed by GP participants out of 12 planned sessions.
Session Rating Scale scores for the 12 sessions completed by GP participants.
Measured: at 3 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jan 2024
- Study start1 Apr 2024
- Primary completionFeb 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Major Depressive DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Experimental Group: Personalised psychomotor therapy: 1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale. The sessions will be based on static and dynamic body exercises involving muscle relaxation, breathing, sensations and moving the body. Control Group: Usual care for 12 weeks with a weekly telephone interview + Duke's Health Scale.
- Masking
- None (open label)
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Esquirol
- Sponsor type
- University, hospital or other
- Collaborators
- Direction Générale de l'Offre de Soins
- Responsible party
- Principal investigator, Aude Paquet, Centre Hospitalier Esquirol
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06234176
- Sponsor's protocol ID
- 2023-A02678-37
- Acronym
- PsyMot-Dep
- Status last verified
- Oct 2026
- First submitted
- 15 Jan 2024
- Last updated
- 30 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Pouilloux G, Henault M, Vinais T, Bodeau N, Laplace B, Paquet A. Study protocol of a randomized controlled trial for the effectiveness of psychomotor therapy on quality of life and psychomotor skills in depression. BMC Psychiatry. 2026 Sep 9;26(1):711. doi: 10.1186/s12888-026-08347-9.
PubMed 42717325
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of Psychomotor Therapy on Quality of Life in Patients With a Major Depressive Disorder: a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06234176
- Acronym / sponsor ID
- PsyMot-Dep / 2023-A02678-37
- Conditions
- Major Depressive Disorder
- Keywords
- psychomotor therapy, quality of life, major depressive disorder, psychomotor profile, sensory processing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 128 participants (estimated)
- Lead sponsor
- Centre Hospitalier EsquirolUniversity, hospital or other
- Collaborators
- Direction Générale de l'Offre de Soins
- Study start
- 1 Apr 2024 (actual)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 31 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life for individuals with depression is unclear.
The investigators will assess how the participants' quality of life and psychomotor profile change over time.
The study aims to compare the quality of life at 3 months between patients who received 3 months of personalised psychomotor therapy in addition to standard treatment and those who received standard treatment alone.
The study lasted for 6 months, and the investigators expects a total of 128 people to participate in this research across several hospital establishments. This study evaluates the effectiveness of two types of treatment, divided into two randomly selected groups.
To participate, individuals must have a medical diagnosis of major depressive disorder (MDD) and be between the ages of 20 and 60.
They must have depressive symptoms with an HDRS score greater than 16 and provide informed consent. They must be treated or hospitalised at the Centre Hospitalier Esquirol or the Centre Hospitalier Henri Laborit (France).
After providing consent, they will undergo an initial clinical interview that evaluates anxiety, self-esteem, pleasure, and quality of life. The therapist assessed the participant's muscle tone, gross motor skills, praxis, manual dexterity, rhythm, processing of sensory information, and body image.
Following the assessment, the participant was randomly assigned to either the experimental or control group.
The experimental group received the usual treatment for depression and underwent psychomotor therapy once a week for 12 weeks.
The control group received the standard treatment for depression and underwent weekly telephone interviews.
An assessment is scheduled at 1 month to evaluate the participant's health status, including any changes to treatment and assessment of anxiety and depressive symptoms.
Another interim check-up is scheduled at 3 months to assess the patient's health status. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.
A final visit will be scheduled at 6 months for an assessment of the participant's health. The interview will also assess any changes to treatment, anxiety and depressive symptoms, quality of life, and psychomotor function.
Detailed description
Hypothesis is that personalised weekly psychomotor therapy for 3 months (period of remission of depression) has a positive influence on the quality of life over time of people with MDD by improving their clinical (anxiety/anhedonia/psychomotor impairment) and psychomotor symptoms.
In this study, the investigators propose to compare the quality of life of two groups of participants: a group receiving one psychomotor therapy session per week in addition to the usual treatments for depression, and a group receiving the usual treatments for depression. The investigators will evaluate changes in quality of life and psychomotor profile over time (at 3 and 6 months).
Based on the results of our pilot study, the psychomotor examination will include an assessment of muscle tone, gross motor skills, praxis, manual dexterity, rhythm using the NP-MOT battery, sensory processing and body image.
Main objective To compare the quality of life at 3 months (M3) between MDD patients receiving 3 months of personalised psychomotor therapy in addition to standard treatment (GP) and those receiving standard treatment alone (GC).
Secondary objectives
- To compare changes in quality of life over time between D0/M3, D0/M6 and M3/M6 in patients in the GP and GC groups; a difference between the groups will be sought.
- Identify the psychomotor assessment items (tone, general motor skills, praxis, rhythm, body image, sensory profile) that differ at inclusion (D0) and 3 months (M3) between the GP and GC groups.
- To identify clinical factors of depression (intensity of depression, anxiety, psychomotor slowing, anhedonia) associated with a difference in psychomotor profile at M3 between the GP and GC groups.
- Identify items predictive of clinical improvement in depression based on psychomotor assessment items (tone, general motor skills, praxis, rhythm, body image, sensory profile) at 6 months (M6) in patients in the GP and GC groups.
- Evaluate at M3, in the GP group, the number of sessions completed and the therapeutic alliance using a scale.
Primary outcome measure Difference at M3 between the GP and GC groups in the quality of life score assessed using the SF-36 (Short-Form 36 Health Survey) scale.
Secondary outcome measures
- Difference between D0 and M3, D0 and M6, M3 and M6 in quality of life scores based on the SF-36. Change in Duke Health Profile scores over the 12 weeks of follow-up (S1 to S12).
- Number and nature of assessment items that differ at inclusion and 3 months between GP and GC using the Neuropsychomotor Function Assessment Battery (NP-MOT), Body Image Questionnaire (BIQ), Multidimensional Assessment of Interoceptive Awareness Version 2 (MAIAI-2), Adolescent/Adult Sensory Profile (AASP) tools
- Depression intensity score on the Hamilton Depression Rating Scale (HDRS), anxiety intensity score on the Hamilton Anxiety Rating Scale (HARS), psychomotor slowing down score on the CORE scale, anhedonia score on the SHAPS scale, and body image score on the QIC and MAIA-2 scales, sensory profile scores on the AASP scale, frequency of tonic-emotional manifestations, sub-scores of the NP-MOT battery, at M3.
- Clinical improvement score: 50% reduction in HDRS score, scores AASP, score QIC, score MAIA-2 and items sub-scores NP-MOT
- Total number of sessions and score on the French version of the Therapeutic Alliance Session Rating Scale at M3
The inclusion criteria for participants in this study are as follows: being between the ages of 20 and 60, having a diagnosis of major depressive disorder according to DSM-5 criteria, having a HDRS score greater than 16 indicating major symptoms, and being hospitalized or receiving care at one of the participating centres.
Additionally, participants must be affiliated with or benefiting from a social security scheme.
The participant and investigator must sign a written consent form that is both free and informed. This must be completed no later than the day of inclusion and before any required research examinations.
Non-inclusion criteria for this study are: psychiatric co-morbidity (excluding tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders), sensory disability or known neurological pathology, history of neurological damage to the brain (especially strokes, tumours, trauma resulting in loss of consciousness lasting more than 10 minutes), and limited functional ability (difficulty moving about, performing manual tasks or moving about).
Participants may be excluded from the study if they are unable to understand the questionnaires or related information, unable to travel to the inclusion centre via personal vehicle or public transport, pregnant or breastfeeding (as declared), subject to compulsory hospitalisation or under guardianship or trusteeship, or lack social protection.
The research is conducted as follows:
- Pre-selection by the coordinating investigator or co-investigator, validation of participation criteria by the referring doctor and information of participants by the referring doctor or coordinating investigator or staff associated with the research.
- Reflection period: between 24 and 72 hours.
- V0: Inclusion Collect of written consent, Socio-demographic data (age, sex, family situation, profession, place of residence, environment), psychiatric history, treatments received (medicinal and non-medicinal), etc.
Quality of life scale (SF36) Clinical assessments: Hamilton Depression Rating Scale (HDRS); Hamilton Anxiety Rating Scale (HARS); psychomotor slowing down scale (CORE), Rosenberg Self-Esteem Scale (EES-10), Anhedonia Scale (SHAPS) Psychomotor assessment: sensory profile (AASP), body image (QIC, MAIA-2), tone (NP-MOT); general motor skills (NP-MOT), rhythm (NP-MOT); praxis (NP-MOT); manual dexterity (PPT) Randomisation: allocation of patients by drawing lots to the GP (personalised psychomotor therapy in addition to standard treatment) or GC (standard treatment) groups.
GP: Personalised psychomotor therapy: 1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale.
The sessions will be based on static and dynamic body exercises involving muscle relaxation, breathing, sensations and moving the body. For each session the Session Rating Scale will be use.
GC: Usual care for 3 months with a weekly telephone interview + Duke's Health Scale.
- V1: visit at 1 month ± 4 days for an interim assessment Treatments received and/or modified in the last 4 weeks Clinical assessments: HDRS; HARS; CORE, EES-10, SHAPS
- V2: visit at 3 months ± 7 days Treatments received and/or modified in the last 3 months Clinical assessments: HDRS; HARS; CORE, EES-10, SHAPS Number of psychomotricity sessions performed Quality of life scale (SF36) Blind psychomotor assessment: AASP, QIC, MAIA-2, NP-MOT
- V3: visit at 6 months ± 7 days Treatments received and/or modified in the last 3 months Clinical assessments: HDRS; HARS; CORE, EES-10, SHAPS Quality of life scale (SF36) Blind psychomotor assessment: AASP, QIC, MAIA-2, NP-MOT Participants in the GC group were offered 12 sessions of psychomotor therapy.
At V2, the psychomotor assessment will be carried out by a psychomotor therapist who has not provided psychomotor therapy to the participant.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Experimental Group: Personalised psychomotor therapy: 1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale. The sessions will be based on static and dynamic body exercises involving muscle relaxation, breathing, sensations and moving the body. Control Group: Usual care for 12 weeks with a weekly telephone interview + Duke's Health Scale.
| Arm | Type | Receives |
|---|---|---|
| Personalised psychomotor therapy group | Experimental | Behavioral: Personalised psychomotor therapy1 psychomotor therapy session of 45 minutes per week for 12 weeks + Duke Health Scale. |
| Usual treatment group | Active comparator | Other: Usual treatmentStandard treatment for depression administered by a doctor + a weekly telephone interview for 12 weeks to administer the Duke Health Scale. |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Diagnosis of depressive episode according to DSM-5 criteria.
- HDRS > 16
- Hospitalized or followed-up in one of the participating centers.
- Affiliated or beneficiary of a social security scheme.
- Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).
Key exclusion criteria (8 listed)
- Psychiatric comorbidity (non-tobacco addiction, eating disorders, bipolar disorder, obsessive-compulsive disorder, schizophrenia and related disorders)
- Sensory impairment or proven neurological pathology
- History of neurological brain damage (including stroke, tumor, trauma resulting in loss of consciousness lasting more than 10 minutes)
- Limited functional ability (difficulty in moving about, performing manual tasks or moving about)
- Inability to understand questionnaires and study information
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Personalised psychomotor therapyAlso: GPThe content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment. The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation. Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions. The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted. During each session, the participant will be required to complete the Duke health profile. | Behavioural | Personalised psychomotor therapy group |
| Usual treatmentAlso: GCParticipants in the GC group will continue to receive their usual depression treatment without any changes to their prescribed therapies. Their participation in the study will involve weekly monitoring of their quality of life using the Duke scale. A nurse or psychomotor therapist will conduct this monitoring during a weekly fifteen-minute telephone interview. The follow-up will begin one week after the inclusion visit and will last for 12 weeks. Telephone appointments will be scheduled jointly with the participant based on their availability. | Other | Usual treatment group |
Primary outcome
Difference in quality of life assessed using the Short-Form 36 Health Survey
Time frame: at 3 month
Difference between GP and GC groups in quality of life score
12 secondary outcomes
Difference in time of quality of life using the Short-Form 36 Health Survey
Time frame: first day to 6th month
Evolution of quality of life using the Duke health profile
Time frame: first day to 6th month
Difference in psychomotor profile
Time frame: 3th and 6 th month
Description of depression intensity using the Hamilton Depression Rating Scale
Time frame: at 3 month
Description of anxiety intensity using the Hamilton Anxiety Rating Scale
Time frame: at 3 month
Description of psychomotor slowing using the CORE scale
Time frame: at 3 month
Description of anhedonia using the Snaith-Hamilton Pleasure Scale
Time frame: at 3 month
Description of body image using the Multidimensional Assessment of Interoceptive Awareness
Time frame: at 3 month
Description of sensory profile using the Adolescent Adult Sensory Profile
Time frame: at 3 month
Frequency of tonic-emotional manifestations
Time frame: at 3 month
Frequency of psychomotor impairment using the NP-MOT battery
Time frame: at 3 month
Frequency of sessions
Time frame: at 3 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Derived from this study: PubMed 42717325Pouilloux G, Henault M, Vinais T, Bodeau N, Laplace B, Paquet A. Study protocol of a randomized controlled trial for the effectiveness of psychomotor therapy on quality of life and psychomotor skills in depression. BMC Psychiatry. 2026 Sep 9;26(1):711. doi: 10.1186/s12888-026-08347-9.
Related trials for Major Depressive Disorder
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
RecruitingPhase 4
Biomarker-Guided Antidepressant Selection
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Recruiting
Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
Major Depressive Disorder, Apathy
RecruitingObservational study
Student Precarity and Psychiatry
Depressive Disorder, Major, Generalized Anxiety Disorder
Not yet recruiting
Acute Intermittent Hypoxia Therapy for Depression
Major Depressive Disorder (MDD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Personalised psychomotor therapy and Usual treatment in people with Major Depressive Disorder, run by Centre Hospitalier Esquirol at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aude PAQUET, Dr (+33555431127, aude.paquet@ch-esquirol-limoges.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in quality of life assessed using the Short-Form 36 Health Survey (time frame: at 3 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06234176, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.